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INHIBITION OF INFLAMMATORY CYTOKINES – POTENTIAL NEW 
TREATMENT FOR DIABETIC NEPHROPATHY 
AMANDA R. CORREIA 
 
ABSTRACT 	  
 Type II diabetes mellitus is currently on the rise and reaching epidemic 
proportions in the United States. In addition to this increase, the number of cases of 
diabetic complication such as kidney disease has increased. Currently diabetic kidney 
disease is the leading cause for end stage renal disease in the United States accounting for 
nearly half of all cases. Type II diabetes is the result of metabolic, hemodynamic and 
inflammatory alterations within the body. Currently there is a standard of care to treat 
both metabolic and hemodynamic perturbations by enforcing tight glycemic control and 
utilizing anti-hypertensive drugs, most notably RAS inhibitors. These therapeutic 
interventions however, are not sufficient as many patients with type II diabetes will still 
develop diabetic kidney disease therefore another treatment option is imperative. 
Currently there are no treatments available to counteract the adverse inflammatory 
responses associated with type II diabetes which are strong contributors to the 
progression of the diabetic kidney disease. Among the inflammatory parameters studied 
as potential targets for therapeutic intervention the inflammatory cytokine tumor necrosis 
factor-α (TNF-α) stands out among the rest for its multifaceted role in disease 
progression.  
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TNF-α has been shown to both directly and indirectly involved in development 
and progression of diabetic kidney disease. The inflammatory cytokine itself is toxic to 
renal cells initially increasing the permeability of the glomerular filtration barrier and 
contributing to proteinuria which eventually causes cellular apoptosis. TNF-α also 
activates second messengers and up-regulates transcription factors that further contribute 
to the progression of diabetic kidney disease.  
Two TNF-α inhibitors, pentoxifylline and chrysin have stood out among the other 
investigational drugs which have been studied as potential therapeutic options to delay 
the progression of diabetic kidney disease. Pentoxifylline is a methyl-xanthine derivative 
that is currently used to treat peripheral vascular disease. It has shown good effect in 
clinical trials decreasing both urinary TNF-α concentrations as well as urinary protein 
excretion. Chrysin is a natural plant derivative belonging to the flavonoid family and is 
known for its anti-inflammatory and anti-oxidant properties. Currently chrysin has only 
been studied in animal models of diabetic kidney disease but has shown to not only 
decrease concentrations of inflammatory cytokines to control levels and improve renal 
functions but also prevented the histopathological changes associated with diabetic 
kidney disease suggesting that chrysin has the ability to not only slow the progression of 
disease and preserve renal function, it has the ability to prevent the disease from ever 
taking root.  
Diabetic kidney disease is a devastating disease affecting millions of people 
worldwide. It is important for further investigation with these investigational drugs to be 
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performed in large scale clinical trials to produce safety and efficacy data with the end 
goal of becoming approved as new treatments for diabetic kidney disease.      
 
  
	  	   vii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
ABSTRACT ....................................................................................................................... iv	  
TABLE OF CONTENTS .................................................................................................. vii	  
LIST OF TABLES ............................................................................................................. ix	  
LIST OF FIGURES ............................................................................................................ x	  
LIST OF ABBREVIATIONS ............................................................................................ xi	  
INTRODUCTION .............................................................................................................. 1	  
Energy Metabolism ......................................................................................................... 1	  
Hormones of Energy Metabolism ............................................................................... 1	  
Normal Energy Metabolism ............................................................................................ 2	  
Disrupted Energy Metabolism ........................................................................................ 3	  
Type II Diabetes Mellitus ............................................................................................... 4	  
Glomerular Filtration Barrier .......................................................................................... 9	  
Diabetic Kidney Disease ............................................................................................... 11	  
Pathophysiology of Diabetic Kidney Disease ............................................................... 13	  
Renin and Angiotensin II .......................................................................................... 14	  
	  	   viii 
Advanced Glycation End Products ........................................................................... 15	  
Protein Kinase C, Nox and JAK/STAT Pathway ..................................................... 16	  
Inflammatory Cytokines in Diabetic Kidney Disease .................................................. 18	  
Intrarenal Renin Angiotensin System (RAS) ................................................................ 21	  
RAS Inhibition in Treatment of Diabetic Kidney Disease ........................................... 22	  
Epidemiology ................................................................................................................ 23	  
Published Studies .............................................................................................................. 25	  
Pentoxifylline ................................................................................................................ 25	  
Mycophenolate Mofetil ................................................................................................. 30	  
Infliximab ...................................................................................................................... 33	  
FR167653 ...................................................................................................................... 34	  
Pirfenidone .................................................................................................................... 34	  
Pyridoxamine ................................................................................................................ 35	  
Natural Derivatives of Plants ........................................................................................ 36	  
DISCUSSION ................................................................................................................... 41	  
CONCLUSIONS ............................................................................................................... 49	  
REFERENCES ................................................................................................................. 53	  
VITA ................................................................................................................................. 63	  
 
  
	  	   ix 
 
LIST OF TABLES 
 
 
Table Title Page 
1 Factors Contributing to Insulin Resistance 6 
2 Modifiable and Non-Modifiable Risk Factors 
Contributing to Diabetic Kidney Disease 
 
13 
3 Effects of TNF-α on the Kidneys 20 
 
 
  
	  	   x 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Glomerular Filtration Barrier 10 
2 Mechanisms Involved in the Pathogenesis of Diabetic 
Kidney Disease 
 
14 
3 Effect of Pentoxifylline Treatment on Urinary Albumin 
Excretion 
 
27 
4 Effect of Prolonged Administration of PTX 30 
5 Effect of Mycophenolate Mofetil on Body Weight, Blood 
Glucose and UAE in animal models of type II diabetes. 
 
32 
6 Effect of Chrysin on Inflammatory Biomarkers 38 
   
 
 
  
	  	   xi 
LIST OF ABBREVIATIONS 
 
AGE……………………………………………………Advanced Glycation End Product 
AI…………………………………………………………………………….Angiotensin I 
AII………………………………………………………………………...…Angiotensin II 
ACEI………………………………………...…Angiotensin Enzyme Converting Inhibitor 
ARB…………………………………………………...…Angiotensin II Receptor Blocker 
AGT…………………………………………………..…………………..Angiotensinogen 
CTGF…………………………………………………...Connective Tissue Growth Factor 
DKD……………………………………………………………...Diabetic Kidney Disease 
ESRD………………………………………………………….....End Stage Renal Disease 
eGFR………………………………………………..Estimated Glomerular Filtration Rate 
E/C…………………………………………………………………………….Extracellular  
ECM…………………………………………………………………..Extracellular Matrix 
GFR…………………………………………………………….Glomerular Filtration Rate 
ICAM-1…………………………………………………..Intercellular Adhesion Molecule 
IL-1……………………………………………………………………………Interleukin-1 
IL-6……………………………………………………………………………Interleukin-6 
I/C……………………………………………………………………………...Intracellular 
MCP-1…………………………………………………Monocyte Chemoattractant Protein 
MMF………………………………………………………………Mycophenolate Mofetil 
NO……………………………………………………………………………..Nitric Oxide 
	  	   xii 
NF- κB…………...…..Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells 
PTX………………………………………………………………………….Pentoxifylline 
PAI-1……………………………………………………..Plasminogen Activator Inhibitor 
PFD………………………………………………………………………….…Pirfenidone 
PKC………………………………………………………………………Protein Kinase C 
PM………………………………………………………………………..….Pyridoxamine 
ROS……………………………………………………………...Reactive Oxygen Species 
RAGE………………………………………...Advanced Glycation End Product Receptor 
RAS…………………………………………………………….Renin Angiotensin System 
SOCS………………………………………....Suppressors of Cytokine Signaling Proteins 
TGF-β …………………………………………………Transforming Growth Factor Beta 
TNF-α ………………………………………………………Tumor Necrosis Factor Alpha 
UAE…………………………………………………………...Urinary Albumin Excretion 
VEGF………………………………………………...Vascular Endothelial Growth Factor
	  1 
INTRODUCTION 
 
Energy Metabolism 
Hormones of Energy Metabolism 
 
Insulin is an anabolic, peptide hormone composed of 51 amino acids and 
produced by the beta cells of the Islets of Langerhans in the pancreas. Insulin plays a 
major role in energy metabolism and is responsible for maintaining concentrations of 
blood glucose and free fatty acids, insuring these levels do not exceed the upper limit of 
normal. Insulin is stored within secretory granules and upon stimulation by glucose 
(primary stimulus), amino acids and free fatty acids is released into the blood stream via 
exocytosis.  Insulin first enters circulation via the hepatic portal vein where 50% of the 
hormone is degraded in its first pass through the liver, thus the peripheral tissues in which 
insulin exerts its effects do not experience the full concentration of insulin. This hormone 
has a half-life of 5-8 minutes and in addition to being degraded by insulinases in the liver 
it is also degraded in the kidney (Koeppen & Stanton, 2009). 
Insulin receptors are located on the surface of cells where the hormone exerts its 
mechanism of action: the liver, skeletal muscle and adipose tissue. In the liver insulin 
promotes glycogen synthesis and storage and activates both glycolysis and lipogenesis. 
Insulin also works to inhibit the opposing pathways thus inhibiting gluconeogenesis, 
glycogenolysis, ketogenesis and fatty acid oxidation. In skeletal muscle insulin promotes 
glucose uptake, glycogen synthesis and protein synthesis. Insulin also works to inhibit 
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glycogenolysis. Finally in adipose tissue insulin activates the storage of triacylglycerides 
and inhibits lipolysis (McPhee & Hammer, 2009).  
Glucagon is a catabolic, peptide hormone composed of 29 amino acids and is 
produced by the alpha cells of the Islets of Langerhans in the pancreas. Glucagon is the 
antagonizing hormone to insulin in energy metabolism. Similar to insulin, glucagon has a 
short half-life of 3-6 minutes with a quarter being metabolized in its first pass through the 
liver and the remaining 75% metabolized later on by both the kidneys and liver. The 
release of glucagon from alpha cells is stimulated by amino acids and low blood glucose 
and is inhibited by both glucose and insulin (Koeppen & Stanton, 2009). 
Unlike insulin, glucagon exerts its actions solely on one organ, the liver. As a 
catabolic hormone glucagon works to break down stored energy to utilize as fuel. 
Glucagon promotes multiple processes in the liver to achieve this including 
gluconeogenesis, glycogenolysis, fatty acid oxidation and ketogenesis (McPhee & 
Hammer, 2009). In a similar fashion to insulin, glucagon also suppresses the opposing 
actions including glycolysis, glycogen synthesis and lipid synthesis. (Koeppen & Stanton, 
2009) 
 
Normal Energy Metabolism 
Under normal conditions the body experiences two states, fed and fasting. In the 
fed state from a primarily carbohydrate meal the body experiences an increase in insulin 
production while glucagon is inhibited. This promotes glycogen synthesis and storage in 
both the liver and skeletal muscle as well as fat storage in adipose tissue. At the same 
	  3 
time glucose production and ketogenesis in the liver are both inhibited. In the fed state 
from a protein rich meal both insulin and glucagon increase due to stimulation from the 
amino acids released during protein breakdown. Insulin exerts the same actions as during 
a carbohydrate meal but the presence of glucagon allows for the liver to produce glucose 
in order to counterbalance the effects of insulin. In the fasting state the primary hormone 
in action is glucagon. Glucagon stimulation exerts is effects primarily on the liver leading 
to glycogen breakdown. Free fatty acids are also released during fasting and are used for 
fuel by skeletal muscle and the liver for ketogenesis. Although fasting, there is enough 
insulin present to prevent hyperglycemia and ketoacidosis (McPhee & Hammer, 2009). 
 
Disrupted Energy Metabolism 
 
 During a prolonged fast normal energy metabolism is interrupted and if not 
corrected can be extremely dangerous and potentially life threatening. The disruption in 
energy metabolism due to prolonged fasting is similar to what is observed in a patient 
with diabetes mellitus. This perturbation of metabolism leads to further increased levels 
of glucagon and further decreased levels of insulin compared to what is observed during a 
normal fasting state. At this point glycogen stores have been depleted and the only source 
of glucose is from hepatic gluconeogenesis using amino acids as the substrate. Eventually 
the body will switch to ketogenesis to meet its minimal energy requirements (McPhee & 
Hammer, 2009). In diabetic patients glucagon levels may be inappropriately high thus 
mimicking the prolonged fasting state. In type II diabetes mellitus this is the result of 
insulin resistance and pancreatic beta cell dysfunction. This state prevents the inhibition 
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of gluconeogenesis in the liver by insulin leading to hyperglycemia. Insulin resistance is 
also observed in skeletal muscle and adipose tissue leading to increased fat breakdown 
and hyperlipidemia as well as decreased glycogen storage (Medscape, 2014; Scheen, 
2003).  
 
Type II Diabetes Mellitus 
 
Diabetes mellitus is a metabolic disorder characterized by an absolute or relative 
deficiency of insulin resulting in hyperglycemia (Gardner & Shoback, 2011). Insulin 
deficiency is the result of various deficits in insulin production, insulin function or both 
(Center for Disease Control and Prevention (CDC), n.d.). There are four known 
classifications of diabetes mellitus, type 1, type 2, gestational and other specific types 
(Gardner & Shoback, 2011).   
Commonly known as non-insulin dependent or adult onset diabetes, type 2 
diabetes is the clinical manifestation of insulin resistance and impaired insulin secretion 
due to pancreatic beta cell dysfunction (Leahy, 2005;CDC, n.d.; Scheen, 2003). The 
metabolic disturbance observed in type II diabetes causes a response from the immune 
system adding on the classification of not only a metabolic disorder but also an immune 
disorder (Navarro & Mora, 2005). Long-term activation of the immune system due to 
hyperglycemia results in a chronic state of low grade inflammation in patients with type 
II diabetes that results in disease instead of repair (Navarro & Mora-Fernández, 2006).  
Type II diabetes mellitus is the result of many contributing factors, both genetic 
and environmental (Table 1), which together stress glucose homeostasis causing an 
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imbalance between the insulin required by the body and the insulin produced by 
pancreatic beta cells (Gardner & Shoback, 2011). Regardless of how type II diabetes 
develops a common phenotype known as the type II diabetes triad is present in all 
patients. The triad consists of pancreatic beta cell dysfunction, insulin resistance 
manifested as impaired glucose clearance by skeletal muscle and overproduction of 
hepatic glucose (Leahy, 2005). Once insulin resistance takes root hyperglycemia will 
ensue and continue to exacerbate this condition thus creating a pathological feedback 
mechanism (Scheen, 2003). 
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Table 1 – Factors Contributing to Insulin Resistance (Table amended from Gardner & 
Shoback, 2011) 
 
Pre-receptor Insulin autoantibodies 
Reduced transendothelial transit 
Primary defect in insulin 
signaling 
Insulin receptor mutations 
Leprechaunism (complete) 
Rabson-Medenhall syndrome (partial) 
Defects in other genes involved in insulin signaling 
Type A (mild) 
Defects in other genes involved in insulin signaling 
Insulin receptor autoantibodies (Type B) 
Ataxia telangiectasia syndrome 
Secondary to other 
endocrine disorders 
Cushing syndrome 
Acromegaly 
Pheochromocytoma 
Glucagonoma 
Hyperthryoidism 
Insulinoma 
Secondary to other disorders Visceral obesity 
Stress (infection, surgery, etc) 
Uremia 
Hyperglycemia (mild resistance seen in type 1 
diabetes) 
Liver disease 
Cytogenetic disorders (Down, Turner, Klinefelter) 
Neuromuscular disorders (muscular dystrophies, 
ataxias, muscle inactivity) 
Congenital lipodystrophies/lipoatrophy 
Acquired lipodystrophy 
Secondary to normal 
physiologic states 
Puberty 
Pregnancy 
Starvation 
Secondary to medications Glucocorticoids 
Atypical antipsychotic drugs 
Antiretroviral protease inhibitors 
Nicotinic acid 
Thiazide diuretics 
Oral contraceptive 
Progesterone 
β blockers  
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Insulin resistance and pancreatic beta cell dysfunction work together to potentiate 
type II diabetes, thus one does not cause the other as previously believed. Insulin 
resistance is an important risk factor for the development of type II diabetes however it is 
not causative. Patients with insulin resistance can also have plasma glucose levels within 
normal limits, the transition from normoglycemic to impaired glucose tolerance and 
eventually diabetes is the result of beta cell dysfunction (Leahy, 2005). 
Insulin resistance is noted in the cells of skeletal muscle, liver and adipose tissue. 
Insulin resistance is caused by a multitude of factors, however, there seems to be three 
commonalities among the majority of cases: aging, lack of exercise and poor diet 
(Scheen, 2003). There are three postulated mechanisms for the cause of insulin 
resistance. First, insulin down regulates its own receptor via negative feedback and 
receptor mediated endocytosis. Second, insulin activates serine/threonine kinases which 
in turn inactivate insulin receptors and/or insulin receptor proteins. Finally it is believed 
insulin receptors and/or insulin receptor proteins concentrations may be decreased due to 
suppressors of cytokine signaling proteins, key regulatory proteins of the inflammatory 
process (Koeppen & Stanton, 2009; Tamiya, Kashiwagi, Takahashi, Yasukawa, & 
Yoshimura, 2011). The suppressors of cytokine signaling proteins are a family of proteins 
composed of SOCS-1 through SOCS-7. SOCS-1 and SOCS-3 are the two members 
involved in insulin resistance. SOCS-1 and SOCS-3 bind to different domains of the 
insulin receptor preventing insulin receptor substrate binding thereby interfering with 
insulin signaling leading to resistance (Ueki, Kondo, & Kahn, 2004). 
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Obesity also plays a major role in insulin resistance as well as the development of 
type II diabetes with an emphasis on body fat distribution. People with increased central 
fat mass experience decreased insulin sensitivity compared to people with fat distributed 
elsewhere throughout the body. Type II diabetics also experience ectopic fat 
accumulation meaning adipocytes are unable to accommodate increasing amounts of 
trigycerides therefore these are stored in other tissues of the body including insulin 
sensitive tissue (skeletal muscle, liver and endocrine pancreas) thus contributing to 
insulin resistance (Scheen, 2003). Obesity has also been associated with enhanced 
production of suppressors of cytokine signaling proteins, which as previously mentioned, 
work to contribute to insulin resistance (Ueki et al., 2004). 
The ability of adipose tissue to produce pro-inflammatory cytokines also 
contributes to insulin resistance in obesity related type II diabetes (Gardner & Shoback, 
2011). Adipose tissue releases the main inflammatory cytokines involved in diabetes and 
is responsible for maintaining the chronic low grade inflammation observed in type II 
diabetes mellitus (Navarro & Mora, 2005). As fat stores increase in the body the amount 
of free fatty acids and proinflammatory adipokines increase. As a result macrophages are 
recruited to the adipose tissue and subsequently activated. Activated macrophages release 
multiple cytokines such as tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), and 
nitric oxide (NO). These molecules increase adipocyte resistance to insulin further 
potentiating the release of proinflammatory cells thereby initiating a positive feedback 
mechanism promoting chronic inflammation and insulin resistance (Gardner & Shoback, 
2011).  
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Insulin deficiency is also present in patients with type II diabetes due to 
pancreatic beta cell deficit and apoptosis. There are three main mechanisms by which this 
insulin deficiency occurs. First there is a genetic defect, although this has not yet been 
confirmed in patients with type II diabetes (Scheen, 2003). The next proposed mechanism 
is the “thrifty phenotype hypothesis” which suggests that malnutrition while in utero 
effects the development of beta cells resulting in deficient insulin secretion (Scheen, 
2003). Finally it is believed than an unfavorable metabolic environment contributes to 
insulin deficiency and the overall development of type II diabetes (Scheen, 2003). The 
increased concentrations of glucose and non-esterified free fatty acids observed in type II 
diabetes are toxic to cells. The ectopic deposition of fat in beta cells results in increased 
synthesis of nitric oxide that causes damage to the cells eventually leading to apoptosis 
thus contributing to beta cell and insulin deficiency (Scheen, 2003).   
 
Glomerular Filtration Barrier 
The glomerular filtration barrier (Figure 1) is composed of three layers whose 
physical characteristics determine the rate of filtration as well as the composition of the 
filtrate (Costanzo, 2013). The first layer of the barrier is the glomerular endothelium. The 
glomerular endothelium is covered by a glycocalyx composed of proteoglycans and 
glycosaminoglycans (Maezawa, Takemoto, & Yokote, 2015). Endothelial cells have 
pores ranging from 70-100nm in diameter and allow the passage of fluid, dissolved 
solutes and plasma proteins. The second layer of the glomerular filtration barrier is the 
basement membrane which itself has three layers: lamina rara interna, lamina densa, and 
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lamina externa. The lamina rara interna is fused to the glomerular endothelium, the 
lamina densa lies in the middle of the basement membrane and the lamina externa is 
fused to the final layer of the filtration barrier composed of specialized epithelial cells 
known as podocytes.  
 
Figure 1: Glomerular Filtration Barrier. The glomerular filtration barrier is composed of three 
layers: endothelium, basement membrane and terminally differentiated epithelium known as 
podocytes. These three layers impose both size and electrostatic barriers preventing the passage 
of large, negatively charged molecules from passing out of the blood and into the urine. 
(Costanzo, 2013) 
 
The basement membrane permits fluid and dissolved solutes to pass through 
however plasma proteins are not filtered through this layer (Costanzo, 2013). As 
previously mentioned, podocytes are specialized epithelial cells that form the final layer 
of the glomerular filtration barrier. Podocytes provide physical support to the glomerulus 
and contain branching, interdigitating structures known as pedicels. The pedicels form 
filtration slits 25-60 nm in diameter, that are covered by a thin diaphragm composed of 
nephrin. The filtration slits impose the greatest size restriction of the glomerular filtration 
barrier (Costanzo, 2013; Satchell & Tooke, 2008).  
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In addition to a size restriction imposed by the glomerular filtration barrier, there 
is also an electrostatic restriction to the filtration process. Negatively charged 
glycoproteins are found on all layers of the glomerular filtration barrier impeding the 
filtration of similarly charged particles (Costanzo, 2013). Heparan sulfate is the major 
glycoprotein found attached to both glomerular endothelial cells and basement membrane 
providing the negative charge for the electrostatic filtration barrier. The glomerular 
basement membrane also contains proteins such as laminin, fibronectin and collagen that 
are negatively charged thus contributing to the electronic component of glomerular 
filtration (Ovalle, PhD & Nahirny, 2013). Electrostatics are not as important in regards to 
the filtration of small solutes however it is important in regards to plasma proteins as they 
are also negatively charged and are therefore repelled by the filtration barrier thus are not 
filtered into the urine (Costanzo, 2013).  
 
Diabetic Kidney Disease 
 
There are three key characterizations of diabetic kidney disease (DKD): persistent 
albuminuria which is defined as greater than 300 mg of albumin per day in the urine over 
the course of 3 to 6 months, decline in glomerular filtration rate (GFR) and elevated 
blood pressure. These diagnostic criteria are the clinical manifestations of cellular 
changes occurring in the kidney as a result of hyperglycemia and chronic inflammation 
associated with diabetes (Medscape, 2014). Thickening of the glomerular basement 
membrane is the earliest morphological change associated with diabetic nephropathy. 
The extent of thickening observed is an indication of the severity of disease progression 
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(Medscape, 2014). Hyperglycemia also induces mesangial cell expansion. This is 
believed to be caused by either increased production of matrix proteins or glycosylation 
of matrix proteins. The third cellular change is the result of intraglomerular hypertension 
which causes hardening of the glomeruli (Medscape, 2014). 
 Diabetes directly effects the filtering units of the kidneys causing them to 
breakdown leading to kidney disease and if not properly treated the need for renal 
replacement therapy (National Kidney Foundation, n.d.). The microalbuminuria observed 
in patients with type II diabetes and DKD is the result of ultra-structural changes to the 
glomerular filtration barrier leading to loss of charge selectivity. Reactive oxygen species 
(ROS) are increased in patients with type II diabetes and are known to disrupt the 
glycocalyx of the endothelial layer of the glomerular filtration barrier. ROS decrease the 
production of heparan sulfate thereby decreasing the concentration of negative charge on 
the filtration barrier. It is this alteration to the endothelial layer of the glomerular 
filtration barrier that is believed to initiate microalbuminuria (Satchell & Tooke, 2008).  
In addition to diabetes mellitus there are many other contributing factors that put a 
patient at risk for developing DKD. These can be broken down in modifiable and non-
modifiable risk factors (Table 2). To decrease the risk of developing DKD it is important 
to control as many modifiable risk factors as possible thus the strong emphasis on 
controlling blood pressure and blood glucose in addition to following a balanced diet and 
exercise regimen (Harjutsalo & Groop, 2014).  
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Table 2: Non-modifiable and modifiable risk factors contributing to diabetic kidney disease 
(Harjutsalo & Groop, 2014) 
 
 
 
Pathophysiology of Diabetic Kidney Disease 
 
Diabetic kidney disease is not the result of a single perturbation but rather 
multiple pathways are implicated in the progression of this disease. The three major 
pathways involved are metabolic, hemodynamic and inflammatory. Hyperglycemia 
initiates the disease process by activating many deleterious intracellular mechanisms as 
well as activating the inflammatory pathway. Hemodynamic alterations play a similar 
role as hyperglycemia in that they also activate harmful intracellular pathways as well as 
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enhancing inflammatory mechanisms (Macisaac, Ekinci, & Jerums, 2014). The interplay 
of these pathological mechanisms is illustrated in Figure 2. 
 
 
 
 
 
Figure 2: Mechanisms involved in the pathogenesis of diabetic kidney disease. The metabolic 
alterations observed in diabetic kidney disease are induced by hyperglycemia. Hemodynamic 
alterations associated with disease are incited by the activation of the renin angiotensin system. 
Metabolic and hemodynamic alterations contribute to disease progression in their own right as 
well as enhancing the inflammatory response (Macisaac et al., 2014).  
 
 
Renin and Angiotensin II 
 
The intrarenal renin angiotensin system produces two mediators in the 
pathogenesis of diabetic kidney disease: renin and angiotensin II (AII). The 
hyperglycemia associated with diabetes mellitus stimulates the production of AII as well 
as angiotensinogen (AGT), an inactive precursor to AII. As the concentration of AII 
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increases and it begins to accumulate in the tissue, it stimulates the expression of 
angiotensinogen mRNA. This creates a positive feedback resulting in increased amounts 
of AII which is deleterious to renal cells (Carey, Giacchetti). Renin and AII stimulate the 
production of pro-inflammatory cytokines as well as pro-fibrotic factors including TNF- 
α, IL-1 β, TGF- β, plasminogen activator inhibitor (PAI-1) fibronectin and collagen 1, 
(Alicic & Tuttle, 2014). AII also plays a direct role in the progression of DKD as it 
induces podocyte injury via the NAPDH oxidase pathway which increases production of 
ROS. Renin can also have damaging effects on the kidneys by activating a variety of 
effectors including ERK 1 & 2, TGF- β, as well as hypertrophic and proliferative effects, 
all of which contribute to the pathology of diabetic nephropathy (Mathew, Cunard, & 
Sharma, 2011).  
Advanced Glycation End Products 
Advanced glycation end (AGEs) products directly and indirectly contribute to the 
progression of DKD. AGEs have the ability to cross-link their proteins which directly 
affects the glomerulus causing extracellular matrix expansion as well as 
glomerulosclerosis. AGEs also bind to proinflammatory cytokine receptors on various 
cells including endothelial cells and mesangial cells as well as receptors located on the 
glomerular basement membrane. These receptors are known as RAGEs (receptors for 
advanced glycation products) and the formation of the AGE-RAGE complex has multiple 
implications in disease progression. Receptor binding causes increased gene expression 
of growth factors (TGF- β, VEGF, CTGF), increased inflammatory cytokine (IL-1, IL-6, 
TNF- α) production as well as forming ROS (Alicic & Tuttle, 2014).  
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Protein Kinase C, Nox and JAK/STAT Pathway 
Protein Kinase C (PKC) is found in several different isoforms, some of which 
have roles in the development and progression of DKD, namely PKC- α and PKC- β. 
PKC- α, when activated, up-regulates vascular endothelial growth factor (VEGF) leading 
to proteinuria. PKC- β is directly involved in the renal hypertrophy and sclerosis 
observed in DKD as it upregulates pro-fibrotic factors such as TGF- β, type IV collagen, 
laminin and fibronectin  There are a number of inciting molecules for the activation of 
PKC most notably, hyperglycemia, AGEs, AII and ROS (Alicic & Tuttle, 2014). PKC 
has also been shown to increase expression of Intercellular Adhesion Molecule – 1 
(ICAM-1) on the surface of glomerular and tubulo-interstitial cells. Increased expression 
of ICAM-1 enhances inflammation by promoting intracellular macrophage infiltration. In 
the presence of high glucose these macrophages will produce TFG-β thereby also 
contributing to the glomerular and tubulo-interstitial fibrosis associated with DKD 
(Tuttle, 2005). 
Nox is composed of several multimeric enzyme complexes and itself is a part of 
NADPH oxidase. Nox functions to generate ROS in reaction to increased glucose, AGEs 
and increased amino acids. Nox2 can be found primarily in podocytes, mesangial cells 
and endothelial cells while Nox 4 is found primarily in the glomerulus, proximal tubule 
and distal tubule (Alicic & Tuttle, 2014). The generation of ROS by Nox leads to 
mesangial expansion by inducing extracellular matrix protein synthesis as well as 
podocyte injury, both of which contribute to the albuminuria observed in DKD. ROS also 
up-regulate pro-fibrotic factors leading to fibrosis and apoptosis. ROS are especially 
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harmful as they not only directly cause histological changes in the glomerulus but also 
cause indirect injury with the ability to activate other pathways implicated in the 
pathogenesis of DKD such as PKC (Alicic & Tuttle, 2014).  
The JAK/STAT pathway has also been shown to play a role in the development 
and progression of DKD. JAK is a tyrosine kinase which activates STAT in the 
JAK/STAT pathway leading to cellular proliferation and growth. It has been observed in 
patients with diabetes that JAK/STAT pathway mRNA is overexpressed leading to 
increased collagen production and fibrosis. This pathway is activated by increased 
glucose, AGEs and AII (Alicic & Tuttle, 2014).  
Finally the transcription factor NF-κB (nuclear	  factor	  kappa-­‐light-­‐chain-­‐enhancer	  of	  activated	  B	  cells), a downstream target activated by inflammatory 
cytokines such as TNF- α, plays an important role in the disease progression of diabetic 
nephropathy. Under normal conditions, NF-κB exists as a heterodimer of two proteins, 
p65 and p50, which is bound to inhibitory κB (IκB) proteins. In this inactive state the 
p65/p50 dimer is located in the cytosol of the cell. Upon cellular stimulation by 
inflammatory cytokines the IκB proteins are degraded via IκB kinases thereby activating 
NF-κB. Once activated, the p65 subunit of NF-κB translocates into the nucleus initiating 
transcription of key players in DKD including, TGF-β. In animal models of DKD NF-
κBp65 is markedly increased, thereby confirming the central role this protein plays in 
disease pathogenesis and marking it has a potential therapeutic target (Ahad, Ganai, 
Mujeeb, & Siddiqui, 2014).   
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Inflammatory Cytokines in Diabetic Kidney Disease 
 
Cytokines are peptides which exert effects over neighboring cells in a paracrine or 
juxtacrine fashion as well as retaining the ability to affect itself thus acting in an 
autocrine fashion. The actions of cytokines are carried out upon cytokine binding to 
surface receptors on cells for which they have a high affinity. Cytokines target a vast 
array of cells and produce different actions depending on type of cell and cytokine 
involved (Navarro-González & Mora-Fernández, 2008).  
The hypothesis that inflammatory cytokines played a role in diabetic nephropathy 
was first proposed in 1991 by Hasegawa et al. when the levels of TNF- α and IL-1 found 
in glomerular basement membranes was compared between diabetic and non-diabetic 
rats. It was discovered that the glomerular basement membranes of diabetic rats 
contained a significantly increased amount of TNF- α and IL-1 when compared to non-
diabetic rats (Hasegawa et al., 1991; Navarro-González & Mora-Fernández, 2008).  
It is now known that interleukin-6 (IL-6), interleukin-1 (IL-1), interleukin-18 (IL-
18) and tumor necrosis factor- α (TNF- α) are the major contributing cytokines involved 
in the pathogenesis of DKD (Navarro-González & Mora-Fernández, 2008). These 
inflammatory mediators are responsible for activating a series of mechanisms causing the 
observed histological damage in patients with diabetic nephropathy. Some of the 
pathologies caused by inflammatory cytokine action include but are not limited to “beta 
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cell dysfunction and apoptosis, insulin signaling impairment, systemic endothelial 
dysfunction and altered vascular flow,” (Pan et al., 2013). 
IL-6 has been shown to increase the width of the glomerular basement membrane, 
the expression of fibronectin as well as the permeability of endothelial cells, all of which 
occur in the early stages of disease progression (Elseweidy, Elswefy, Younis, & 
Zaghloul, 2013; Navarro-González & Mora-Fernández, 2008). IL-1 also increases the 
permeability of endothelial cells as well as increasing the thickness of the glomerular 
basement membrane by stimulating both mesangial cell proliferation and extracellular 
matrix synthesis. The effects of IL-18 are not definitely known; however it is believed 
IL-18 up-regulates other inflammatory cytokines and is involved in the apoptosis of 
glomerular endothelial cells (Duran-Salgado & Rubio-Guerra, 2014). IL-18 has also been 
associated with urinary albumin excretion rate (Navarro & Mora-Fernández, 2006).  
TNF- α plays a central role in the pathogenesis of diabetic kidney disease, 
contributing to many of the observed pathologies of DKD (Table 3). It is synthesized by 
monocytes and macrophages as well as intrinsically in the kidney (Navarro & Mora-
Fernández, 2006). TNF- α exerts its deleterious effects through multiple mechanisms 
such as activating second messengers, up-regulating transcription factors and growth 
factors as well as stimulating the production of cell adhesion molecules (Duran-Salgado 
& Rubio-Guerra, 2014). TNF- α alters key regulatory genes involved in glucose and lipid 
metabolism thereby perturbing insulin signaling and cellular glucose uptake. 
Hemodynamics are also altered by this cytokine as TNF-α stimulates the release of 
vasoconstricting compounds from mesangial cells. This action decreases glomerular 
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blood flow thereby decreasing GFR (Navarro & Mora-Fernández, 2006). In addition to 
the various mechanisms TNF-α activates this cytokine in and of itself is harmful to the 
kidneys. TNF-α is cytotoxic to mesangial and epithelial cells leading to apoptosis as well 
increasing the permeability of the glomerular filtration barrier (Elseweidy et al., 2013; 
Navarro & Mora-Fernández, 2006).  
 
 
Table 3: Effects of TNF- α on the Kidneys (Navarro & Mora-Fernández, 2006) 
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The inflammatory cytokines transforming growth factor – β (TGF- β) and 
vascular endothelial growth factor (VEGF) are also directly involved in the pathogenesis 
of diabetic nephropathy. TGF- β expression is increased in the presence of 
hyperglycemia, and in conjunction with VEGF contributes to the increased in size of the 
glomerular cells as well as the increased collagen synthesis observed in patients with 
diabetic nephropathy (“Medscape, 2014,” 2014).  
 
Intrarenal Renin Angiotensin System (RAS) 
 
The kidneys utilize the renin angiotensin system to perform one of its major 
functions: that of regulating blood pressure. Intrarenal RAS contains all of the same 
components of systemic RAS including renin, angiotensinogen (AGT), angiotensin I (AI) 
and angiotensin II (AII). Activation of the RAS begins with the production of the enzyme 
renin by the juxtaglomerular cells found in the renal afferent arteriole. The production 
and secretion of renin is stimulated by low blood pressure which is sensed by the afferent 
arteriole. Renin then enters the blood stream where it encounters AGT which is produced 
by cells of the proximal tubule. Renin cleaves AGT into AI which is subsequently 
hydrolyzed into the biologically active AII. AII is a potent vasoconstrictor thereby 
increasing peripheral resistance and blood pressure in order to correct the inciting 
hypotensive state (Carey & Siragy, 2003; Singh & Williams, 2009).  
AII has two receptors in the kidneys, AT1 which is located throughout the kidneys 
on vascular smooth muscle cells and AT2 which is also located throughout the kidney on 
afferent arterioles, endothelial cells, interstitial cells and proximal tubule cells. The 
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actions of AII are mainly carried out via AT1 receptors including arteriole 
vasoconstriction, sodium reabsorption by the tubules, and inhibition of pressure-
natriuresis. Binding of AII to AT2 receptors causes the opposing actions produced by 
binding to AT1 receptors thus promoting vasodilation and decreased renal vascular 
resistance (Carey & Siragy, 2003).   
 
RAS Inhibition in Treatment of Diabetic Kidney Disease 
 
In addition to strict glycemic control the current standard of care for diabetic 
nephropathy is treatment with a RAS inhibitor, either an angiotensin II receptor blocker 
(ARB) or an angiotensin converting enzyme inhibitor (ACEI). Angiotensin II 
preferentially vasoconstricts the postglomerular (efferent) arterioles causing an increase 
in glomerular pressure which then contributes to the progression of renal disease. Thus 
inhibition of the RAS assists in slowing the progression of chronic nephropathies 
(Remuzzi, Perico, Macia, & Ruggenenti, 2005).  
ARBs perform effective RAS inhibition by preventing the binding of AII to the 
AT1 receptor. This directly inhibits the vasoconstriction of the postglomerular arteriole 
thereby preventing an increase in glomerular pressure (Remuzzi et al., 2005). Multiple 
studies, most notably the Irbesartan in Diabetic Nephropathy Trial and the RENAAL 
trial, have found that implementing the use of an ARB in treating diabetic nephropathy 
reduced the risk of serum creatinine doubling, i.e., of a reduced GFR, end stage renal 
disease and death (Brenner et al., 2001; Lewis et al., 2001; Remuzzi et al., 2005). The use 
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of ARBs also promotes AT2 activity providing added renal protection (Carey & Siragy, 
2003).  
ACE inhibitors interfere with the RAS by preventing the conversion of AI to AII 
(Remuzzi et al., 2005). The inhibition of ACE also prevents the degradation of 
bradykinin. Bradykinin is an endogenous vasodilator that has been shown to have 
renoprotective properties due to its ability to decrease blood pressure (Carey & Siragy, 
2003). In addition to lowering blood pressure, ACEIs decrease proteinuria associated 
with diabetic nephropathy (Remuzzi et al., 2005).  
Combination therapy, dosing with an ARB and an ACEI poses great risk for the 
patient. Many studies have shown combination therapy increases the subjects risk for 
adverse cardiovascular events, hyperkalemia and acute kidney injury. In comparison to 
single ACEI or ARB therapy, combination therapy does not provide greater renal 
protection or antiproteinuric effect. The risk of using combination therapy outweighs the 
benefit thereby eliminating this as a potential therapy for patients with DKD (Fried et al., 
2013; Mann et al., 2008; Parving et al., 2012).  
 
Epidemiology 
Currently 29 million Americans are estimated to have diabetes mellitus, 
accounting for slightly over 9% of the US population. An additional 86 million adults in 
the United States are estimated to have pre-diabetes, a condition of elevated blood sugar 
but not so high as to be diagnosed with type II diabetes. Of those 86 million adults, 15% - 
30% will develop type II diabetes over the next five years (CDC, n.d.).  
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As the rates of diabetes mellitus continue to increase so do the number of cases of 
DKD. Diabetic kidney disease reaches peak incidence 15-20 years post DM diagnosis 
(Harjutsalo & Groop, 2014). Due to the current obesity epidemic the United States is 
facing, type II diabetes mellitus is on the rise, especially in the younger population 
(Harjutsalo & Groop, 2014; CDC, n.d.). With disease onset occurring at younger ages 
more diabetic patients will develop DKD and eventually End Stage Renal Disease 
(ESRD) (Harjutsalo & Groop, 2014). Currently DKD is the leading cause of end stage 
renal disease in the United States accounting for nearly 50% of all ESRD cases (de Boer 
et al., 2011; Mitka, 2004). Rates of ESRD due to type II diabetes mellitus have increased 
the greatest in the youngest age group, patients aged 30-44 (Harjutsalo & Groop, 2014).  
Despite increased patient use of glucose lowering medications as well as 
medications that inhibit the RAS, the incidence of DKD is increasing, clearly conveying 
the need for additional agents to combat this devastating disease (de Boer et al., 2011). Of 
the three major pathways that contribute to the progression of DKD, two (metabolic and 
hemodynamic) currently have drugs on the market and are proving not to be enough to 
treat disease progression. With this in mind, implementing therapy to interfere with and 
inhibit the inflammatory contribution to this disease is the next logical step. 
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Published Studies 
 
Pentoxifylline 
 
Pentoxifylline (PTX) is an erythrocyte phosphodiesterase inhibitor derived from 
methylxanthine and is currently on the market to treat peripheral vascular disease 
(Navarro et al., 1999; Navarro, Mora, Muros, & García, 2005). The inhibition of 
phosphodiesterase results in an increase in intracellular cyclic AMP. This promotes the 
integrity of the erythrocyte membrane and increases resistance to deformity. In addition 
to its effects on erythrocytes, PTX also increases fibrinolytic activity thus decreasing 
blood viscosity allowing blood to flow more easily (Behcets, n.d.).  
PTX also has known immunoregulatory and anti-inflammatory properties 
(Navarro et al., 1999). The mechanism behind which PTX derives its renoprotective 
function is largely unknown however investigators have come to attribute it to PTX’s 
ability to decrease concentrations of proinflammatory cytokines (McCormick et al., 
2008). PTX inhibits TNF- α mRNA. In doing so PTX prevents transcription and 
synthesis of TNF- α. Decreasing the concentration of TNF- α greatly aids in protecting 
renal function due to the vast role TNF- α plays in the pathogenesis of DKD (Navarro-
González & Mora-Fernández, 2008).  
A 2005 study by Navarro et al. showed that the addition of Pentoxifylline to 
normotensive patients on an ARB provided a greater renoprotective and antiproteinuric 
effect compared to those patients on an ARB and placebo. This study utilized a sample of 
61 subjects with nephropathy due to type II diabetes who were normotensive and were 
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taking an ARB at the recommended dose to treat diabetic nephropathy. The subjects were 
then randomized in a double blind fashion, 30 subjects received treatment with 
Pentoxifylline and 31 subjects received treatment with placebo. Prior to initiation of 
treatment all subjects were noted to have similar baseline renal function, blood pressure, 
metabolic control, albuminuria as well as serum and urinary TNF- α concentrations. At 
the end of the study the treatment group was noted to have decreased albuminuria as well 
as decreased serum and urinary TNF- α concentrations compared to the control group as 
depicted in Figure 4. Renal function, blood pressure and metabolic control remained the 
same across both treatment and control groups. This is an important discovery because it 
means that the decrease in albuminuria and TNF- α concentrations is due to 
Pentoxifylline and not due to hemodynamic or metabolic changes (Figure 3) (Navarro et 
al., 2005).  
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Figure 3: Effect of pentoxifylline treatment on urinary albumin excretion. Baseline urinary 
albumin excretion rates for both placebo and pentoxifylline treatment groups were similar at 
about 900mg/day. End of study data collection showed a significant decrease in urinary albumin 
excretion rate for patients treated with pentoxifylline compared to placebo as noted by the p value 
of less than 0.001. (Navarro et al., 2005) 
 
 
 
A short clinical trial was run by Ghorbani et al. (2011) to test the hypothesis that 
the addition of Pentoxifylline to combination therapy with an ARB and an ACEI would 
result in a further decrease in urinary protein excretion than combination therapy alone. 
This trial took place over the course of 6 months with 100 subjects and was conducted in 
a double blind and randomized fashion. All patients received 50mg of losartan (ARB) 
and 15mg of enalapril (ACEI) daily. In addition to this treatment regimen subjects in the 
treatment group received 400mg of PTX daily. The treatment group experienced 
significant decreases in urinary protein excretion after three months and six months 
whereas proteinuria did not change throughout the course of the study for the control 
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group. The treatment group also experienced renal protection from PTX treatment as 
noted by the increase in creatinine clearance after six months of treatment. The control 
group did not experience any improvement in creatinine clearance through the duration of 
the study. These results suggest PTX may attenuate disease progression as well as 
maintain and potentially improve renal function in patients with type II diabetes 
(Ghorbani, Omidvar, Beladi-Mousavi, Lak, & Vaziri, 2012).  
In 2014 Navarro et al. once again investigated PTX over the course of two years 
in patients with type II diabetes and hypothesized that the addition of PTX to a patient 
maximum tolerated daily dose of an ARB or ACEI would delay the progression of 
diabetic nephropathy as well as restore kidney function. In an open label study with PTX 
investigators compared estimated glomerular filtration rate (eGFR), urinary albumin 
excretion (UAE) and urinary TNF- α concentrations in patients taking PTX and patients 
not taking PTX. As seen previously, the addition of PTX to an ACEI or ARB regiment 
significantly decreased proteinuria. All subjects had a similar baseline UAE with the 
control group having an average UAE of 1000mg/d and the experimental group having 
an average UAE of 1100mg/d. End of study measurements showed that the control group 
average UAE increased by 5.7% to 1117mg/d while the PTX group average UAE 
decreased by -14.9% to 973mg/d. Thus there was an overall 20.6% difference in average 
UAE between groups in favor of those subjects taking PTX. As prior studies have shown, 
urinary TNF- α concentrations decreased in subjects taking PTX and did not change in 
control subjects. Finally investigators in this study looked at PTX effects on eGFR to 
determine if PTX could protect renal function. End of study measurements showed a 
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significant mean difference in eGFR of 4.3 ml/min per 1.73m2 in favor of the PTX group. 
The between group difference in eGFR did not reach statistical significance until 1 year 
into the trial and remained statistically significant until the trial concluded. This suggests 
that long term administration of PTX is necessary in order to preserve renal function. 
Blood pressure and glycemic control did not differ significantly in either group thus 
attributing the decrease in proteinuria and preservation of renal function to PTX 
(Navarro-González et al., 2015).  
As increasing evidence was published indicating Pentoxifylline as a promising 
new drug therapy for DKD it was important to establish just how long a subject would 
need to be dosed to observe the renoprotective effect of PTX. In a 2009 study involving 
streptozotocin induced diabetic rats, Han et al. hypothesized PTX is most effective when 
administered for a period of time greater than four weeks (Figure 4). The rats were split 
into three groups, control, diabetic and untreated, and diabetic treated with PTX. 
Researchers compared body weight, kidney weight, glucose levels, urinary protein 
excretion and urinary monocyte chemoattractant protein (MCP-1) among the three groups 
at four weeks and again at 8 weeks. It was observed that at four weeks of treatment, 
diabetic rats treated with PTX did not experience a decrease in urinary protein excretion 
when compared to untreated diabetic rats; however, urinary protein excretion was 
attenuated in PTX treated rats after eight weeks of treatment. In contrast, PTX treated rats 
did experience a decrease in urinary MCP-1 at four weeks and this continued through the 
eight weeks of treatment. Investigators concluded that the anti-inflammatory effect of 
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PTX is apparent within the early stages of treatment and the antiproteinuric effect is 
experienced with prolonged treatment (Han, Han, Kim, Kang, & Cha, 2010).  
 
 
 
Figure 4: Effect of prolonged administration of PTX. Administration of pentoxifylline for a 
period of four weeks does not provide significant renal protection for rat models of type II 
diabetes as evidenced by the significant amount of proteinuria. Renal protection is observed after 
eight weeks of administration of pentoxifylline in rat models of type II diabetes as seen by the 
significant decrease in proteinuria compared to untreated diabetic rats. These results support the 
hypothesis that prolonged administration of pentoxifylline heightens its renoprotective nature. 
CTR: control group, DM: diabetic control group, PTX: pentoxyifylline treatment group (Han et 
al., 2010) 
 
 
Mycophenolate Mofetil 
Mycophenolate Mofetil (MMF) is an immunosuppressive drug with known 
antilymphocyte and antinflammatory properties. MMF’s anti-inflammatory property 
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derives from its ability to prevent leukocyte recruitment at sites of inflammation (	  Rx	  List,	  The	  Internet	  Drug	  Index,	   n.d.). In a 2002 study by Utimura et al. MMF was used to 
treat Munich-Wistar rats with streptozotocin induced diabetes. This study compared three 
groups of rats, a control (non-diabetic rats), diabetic rats treated with insulin and finally 
diabetic rats treated with both insulin and MMF. The study took place over a period of 
eight months during which it was observed that diabetic rats treated with both insulin and 
MMF had significantly decreased albuminuria in comparison to diabetic rats treated with 
only insulin (Figure 5). MMF treated rats did not display any changes in blood pressure, 
blood glucose concentration or glomerular dynamics when compared to the control group 
and diabetic rats treated with insulin group, thus the antiproteinuric effect of MMF can be 
solely attributed to the immunosuppressive properties of this drug (Utimura et al., 2003).  
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It was also observed that MMF treated rats did not have glomerular macrophage 
infiltration nor did these rats experience glomerulosclerosis. Interestingly, it was noted 
that although at two months the glomeruli had been infiltrated with macrophages in rats 
with diabetes, the glomeruli did not express any other injury associated with diabetes. 
Thus glomerular macrophage infiltration is an early step in the pathogenesis of diabetic 
nephropathy and precedes glomerular injury. Further investigation is warranted to 
determine if early treatment with MMF can prevent glomerulopathy (Utimura et al., 
2003).  
 
Infliximab 
 
 Infliximab is a TNF-α inhibitor that is currently approved to treat autoimmune 
diseases such as rheumatoid arthritis, Crohn’s disease and ulcerative colitis (Medline Plus 
n.d.). This drug is also currently under investigation as a potential treatment for DKD. In 
a 2007 study involving streptozotocin induced diabetic rats, investigators hypothesized 
TNF-α inhibition would decrease urinary albumin excretion thus delaying the progression 
of diabetic nephropathy. Post induction of diabetes, infliximab treated rats received 
injections of the study drug every four weeks for a total study duration of twelve weeks. 
Infliximab treatment decreased urinary TNF-α excretion significantly on weeks 1, 4 and 
12 when compared to untreated diabetic rats. However, infliximab treatment was unable 
to reduce urinary TNF-α excretion to levels comparable to non-diabetic control rats. On 
the other hand, treatment with infliximab did decrease urinary protein excretion 
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significantly that achieved similar concentrations as non-diabetic control rats. Although 
other parameters of disease progression were not evaluated in this study the results do 
suggest that targeting TNF-α with infliximab has the potential to attenuate some of the 
disease process of diabetic nephropathy (Moriwaki et al., 2007).  
 
FR167653 
 
 In the previously mentioned study by Moriwaki et al. (2007) the investigators also 
looked at another inhibitor of TNF-α to potentially decrease urinary protein excretion in 
streptozotocin induced diabetic rat models of DKD. FR167653, a known potent inhibitor 
of p38 MAPK, not only has been shown to inhibit TNF-α but also IL-1 in in vitro studies. 
In contrast to infliximab, FR167653 was administered orally to streptozotocin induced 
diabetic rats over a period of twelve weeks. FR167653 treated rats experienced very 
similar results as those treated with infliximab. They displayed decreased urinary TNF-α 
concentrations that did not reach control concentrations and also experienced decreased 
urinary protein excretion which were comparable to control concentrations (Moriwaki et 
al., 2007).  
 
Pirfenidone  
 
 TGF- β is another cytokine of interest in treating DKD for not only its pro-
inflammatory properties but also its pro-fibrotic properties. Pirfenidone (PFD) is an anti-
inflammatory, anti-fibrotic agent derived from pyridone which has been investigated as a 
possible treatment for DKD. Pirfenidone is a known TGF- β inhibitor and in animal 
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models has shown to also decrease concentrations of TNF- α. Pirfenidone exerts its 
inhibitory effects on TGF- β in a multitude of ways. PFD can act to block the TGF- β 
promoter, inhibit the secretion of TGF- β proteins as well as inhibit the phosphorylation 
of SMAD2, a downstream target of TGF- β. This inhibition results in decreased matrix 
protein accumulation as well as reduced expression of mesangial matrix genes (Mathew 
et al., 2011). It is hypothesized that the inhibition of TGF- β will decrease renal fibrosis 
thereby sustaining optimal renal function for a longer period of time thus delaying the 
progression of diabetic kidney disease (Sharma et al., 2011).  
 
Pyridoxamine  
 
 Pyridoxamine (PM) is an investigational product currently being tested for the 
treatment of diabetic kidney disease. PM is derived from vitamin B and has been shown 
to inhibit the formation of AGEs by trapping their intermediate form(Chen & Francis, 
2012; Elseweidy et al., 2013). PM also scavenges ROS which in addition to inhibiting 
AGEs may provide renal protection in DKD (Lewis et al., 2012). In a study evaluating 
PM in alloxan induced diabetic rats; it was shown that after six weeks of treatment with 
PM, pro-inflammatory cytokine gene expression was significantly reduced. In this study 
researchers found that PM did not improve renal function but rather attenuated some of 
the key players in the pathogenesis of DKD (Elseweidy et al., 2013).  
 Although pyridoxamine did not seem to have an apparent renoprotective effect in 
animal studies, this potential treatment made its way into human clinical trials. One such 
study was a double blind, randomized, placebo controlled study by Lewis et al. in which 
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subjects were placed into one of three groups: placebo, pyridoxamine (Pyridorin) 150 mg 
twice a day, or pyridoxamine 300 mg twice a day. Subjects in each group had similar 
baseline characteristics and after one year of therapy it was determined that pyridoxamine 
failed to protect renal function and prevent an increase in serum creatinine. Accordingly, 
with the investigators’ secondary endpoints each group was broken down into tertiles 
based on baseline creatinine. When examined in these groups, it was observed that 
subjects in the first tertile (those with the lowest baseline serum creatinine and thus the 
greatest baseline renal function) of both treatment groups did experience a slowing of 
disease progression. From this, investigators concluded that pyridoxamine is effective in 
protecting renal function in those subjects with greater baseline renal function. This was 
based on both the observed data and the fact that AGE formation occurs early in the 
disease process. Therefore those subjects who have the greatest intact renal function will 
benefit more from pyridoxamine than those who are far more progressed in the disease 
(Lewis et al., 2012).  
 
Natural Derivatives of Plants  
 
 Researchers have not only looked towards synthetic chemical compounds to 
ameliorate diabetic kidney disease but have also investigated natural compounds such as 
flavonoids and curcumin. These products are known for the anti-inflammatory and anti-
oxidant effects and are currently widely used in pharmacy with little known side effects 
thus presenting as potential therapeutic agents to attenuate or even prevent the chronic 
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inflammation and its side effects observed in DKD (Ahad et al., 2014; Fang et al., 2015; 
Pan et al., 2013).  
 
 One such flavonoid that has been investigated for its potential therapeutic use is 
chrysin. Chrysin is a naturally occurring compound with anti-inflammatory and anti-
oxidant effects found in plant extracts and honey. Ahad et al treated streptozotocin 
induced diabetic rats for 16 weeks to determine the potential benefits of chrysin. At the 
end of the 16 week treatment period, rats treated with chrysin not only showed 
significantly reduced concentrations of inflammatory cytokines but had concentrations of 
these cytokines similar to that of control, non-diabetic rats (Figure 6). Compared to 
untreated diabetic rats, chrysin treated rats had decreased serum creatinine, BUN and 
proteinuria as well as increased creatinine clearance thus implying chyrsin has the ability 
to improve renal function in diabetic kidney disease. At the end of the treatment period 
the rats were sacrificed and all had the left kidney removed in order to determine the 
histological effects of chrysin. Untreated diabetic rats displayed the expected 
histopathology of diabetic nephropathy with thickened glomerular basement membranes 
and expanded mesangial matrices. In comparison, chrysin treated diabetic rats displayed 
histology resembling the control, non-diabetic rats, with normal glomerular basement 
membranes and normal mesangial matrices. Researchers believe that through the 
inhibition of TNF-α, chrysin was not only able to attenuate the disease process, it was 
able to prevent it (Ahad et al., 2014).  
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Figure 6: Effect of chrysin on inflammatory biomarkers. Treatment with chrysin in type II 
diabetic induced rats maintained non-diabetic control levels of inflammatory biomarkers 
expressed by renal cells. A. Western blot representing protein concentrations of inflammatory 
biomarkers after 16 weeks of treatment. β-actin served as the loading control for cytoplasmic 
proteins and Histone H1 served as the loading control for nuclear proteins.  B. Graphical 
representation of inflammatory protein levels expressed by cultured renal cells after 16 weeks of 
treatment. NC: normal control, DC: diabetic control, Chrysin-N: normal rats treated with chrysin 
at 40mg/kg bw/day, Chrysin-40: diabetic rats treated with chrysin at 40mg/kg bw/day (Ahad et 
al., 2014) 
 
Flavonoid derivatives have also been studied for the treatment of diabetic kidney 
disease with one such derivative being L6H21 (Fang et al., 2015). L6H21 is a derivative 
of chalcone and can be found in plants, spices and teas. In vitro studies have shown 
therapeutic benefit of L6H21 in preventing the progression of diabetic nephropathy. In 
renal NRK-52E cells, L6H21 has been shown to inhibit the expression of inflammatory 
cytokines induced by hyperglycemia. Investigators showed that hyperglycemia induces 
the expression of inflammatory cytokines at both the mRNA and protein level and, 
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pretreatment of NRK-52E cells with L6H21 showed significant inhibition, in a dose 
dependent manner, of inflammatory cytokine mRNA as well as proteins. L6H21 also 
significantly decreases chemokine and cell adhesion molecule expression in addition to 
inhibiting the activation of NF-κB by preventing the degradation of IκB proteins. 
Investigators also compared L6H21 to a known anti-inflammatory agent, curcumin. In all 
cases L6H21 had a greater inhibitory effect than curcumin. L6H21 worked in a dose 
dependent manner, thus higher concentrations had greater inhibitory effect (Fang et al., 
2015).  
 As previously stated curcumin does have an inhibitory effect in vitro, however 
large concentrations are required due to its poor bioavailability (Fang et al., 2015; Pan et 
al., 2013). A curcumin derivative, B06, was engineered to have the same anti-
inflammatory properties with a greater pharmacokinetic profile. Both in vitro and in vivo 
studies have been done which look at the efficacy of B06 in the prevention of DKD. In 
vitro, pretreatment with B06 decreased both the concentrations and transcription of 
inflammatory cytokines, TNF- α and IL-6. B06 also prevented the phosphorylation and 
thus degradation of IκB proteins thereby preventing the activation of NF-κB. In vivo 
study was performed using streptozotocin induced diabetic rats to determine the 
therapeutic effect of B06. Serum concentration of TNF- α and nitric oxide are key 
indicators of inflammation, the greater the concentration of these biomarkers the greater 
the inflammatory process taking place. In B06 treated rats there was no significant 
increase in these inflammatory biomarkers. B06 treated rats also did not experience a rise 
in plasma creatinine nor an increase in kidney weight to body weight ratio as is observed 
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in models of diabetic nephropathy. Finally the histopathological changes observed in 
DKD (GBM thickening, mesangial matrix expansion, and inflammatory cell infiltration) 
were not seen in B06 treated rats (Pan et al., 2013).   
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DISCUSSION 
 
 The current standard of care for treating diabetic kidney disease consists of 
antiproteinuric agents such as angiotensin II receptor blockers and angiotensin converting 
enzyme inhibitors in addition to strict glycemic control. However these agents alone have 
proven not sufficient when it comes to combating diabetic nephropathy. Therefore many 
patients progress to end stage renal disease and experience significant cardiovascular 
events. In some cases ARBs and ACEIs cannot be used due to intolerable side effects 
such as hyperkalemia and angioedema thereby creating an even greater need for 
additional agents to combat this disease (McCormick et al., 2008).  
 With increasing research the role inflammation plays in type II diabetes mellitus 
as well as the progression of diabetic kidney disease has come to light causing 
researchers to target hallmarks of inflammation as possible treatments. Tumor necrosis 
factor-α is one such inflammatory biomarker that has been extensively studied in regards 
to the progression of DKD. TNF-α not only causes vast cellular damage accounting for 
the characteristic histopathological changes of this disease but also contributes to the 
metabolic and hemodynamic perturbations observed in patients with diabetes mellitus 
(Elseweidy et al., 2013). Multiple studies have also shown a positive correlation of 
urinary TNF-α concentration and urinary protein excretion (Moriwaki et al., 2007; 
Navarro-González et al., 2015; Navarro et al., 2003). With such an extensive role in 
disease pathogenesis it is no wonder why TNF-α has been the target of many 
investigational treatments for DKD. 
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 Pentoxifylline has been extensively studied over the course of many years as a 
potential therapy for diabetic kidney disease. Data from multiple studies show that 
addition of PTX to a previously established antiproteinuric regiment (ACEI or ARB) not 
only decreases proteinuria even further but also provides greater renal protection 
(Ghorbani et al., 2012; Navarro-González et al., 2015; Navarro & Mora, 2005). PTX is 
able to exert such effects due to its inhibitory action on TNF-α at the level of 
transcription (Navarro-González et al., 2015). In decreasing the concentration of TNF-α, 
PTX prolongs the deleterious effects of this cytokine on the kidney thereby maintaining 
greater renal function for a longer period of time and delaying time to end stage renal 
disease.   
 Pentoxifylline has shown great promise in studies conducted in type II diabetes 
patients with subsequent diabetic nephropathy; however, these studies are greatly limited. 
Many of these studies come from the same research group who do not always utilize the 
classic double blind, randomized, placebo controlled clinical study protocol. By not 
controlling all parameters of the study as well as knowing which patients are receiving 
experimental treatment introduces the possibility of investigator bias. Also it is important 
for this work to not only be reproducible by the same research group but by multiple 
investigators. These studies also often only looked at a small patient population, this 
decreases the power of these studies and can also lead to type I error in statistical 
analysis. On the other hand, since these studies have produced positive results the next 
step should be to establish a protocol for administration of Pentoxifylline in patients with 
type II diabetes and diabetic nephropathy, which would incorporate a large number of 
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patients and run in a double blind, randomized placebo controlled fashion to increase the 
power of the statistics and minimize potential bias. Long term, large scale trials would 
also produce safety and tolerability data of pentoxifylline in human subjects which would 
reveal to investigators and industry sponsors if this is a drug that warrants further 
investigation. 
 Infliximab and FR167653 are also potential therapeutic options for the treatment 
of DKD due to their inhibitory effect on TNF-α (Moriwaki et al., 2007). These drugs 
have not been introduced into the human population but they have been studied in animal 
models of DKD due to type II diabetes. Both infliximab and FR167653 were shown to 
decrease urinary concentrations of TNF-α as well as restore urinary protein 
concentrations to non-diabetic control levels. Further animal studies are warranted for 
both infliximab and FR167653 to reproduce the results of this study as well as to obtain 
safety information for these drugs. Infliximab is currently used in humans to treat 
autoimmune diseases therefore it has a known safety and tolerability profile which may 
allow for a quicker transition from animal to human subjects (Moriwaki et al., 2007). 
 An additional TNF-α inhibitor has also been studied in regards to diabetic kidney 
disease. Chrysin is a member of the flavonoid family and is known for its anti-
inflammatory properties with little known adverse effect. Although chrysin has not been 
studied in humans, data from animal studies have shown promising results. Not only did 
streptozotocin induced diabetic rats treated with chrysin have improved renal function 
compared to untreated diabetic rats, their kidneys showed no evidence of pathology due 
to DKD. This led researchers to conclude that chrysin could not only delay disease 
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progression, it prevented the disease from taking root (Ahad et al., 2014). With such 
promising results animal studies should be repeated to reproduce the data as well as to 
determine its safety and tolerability. If these results were to be reproduced the next step 
would be to investigate the safety and efficacy of chrysin in the treatment of diabetic 
nephropathy in patients with type II diabetes. It is important for a drug like chrysin to be 
investigated in humans due to its potential to prevent DKD. This would have an 
astronomical effect on the way diabetic patients are currently treated and potentially 
prevent numerous patients from reaching end stage renal disease and the need for renal 
transplantation.  
 Transforming growth factor-β is another inflammatory cytokine that plays a 
central role in the inflammatory contribution to DKD progression and has been targeted 
by therapeutic agents to treat this disease. Many of the pathological mechanisms 
activated by hyperglycemia lead to enhanced production of TGF-β including AGE-
RAGE complex binding and the protein kinase C pathway. Activation of the renin 
angiotensin system also contributes to the production of TGF- β. The enhanced 
production of TGF-β results in glomerular cell hypertrophy as well as increased collagen 
synthesis leading to fibrosis and glomerulosclerosis (Medscape, 2014).  
Pirfenidone is a known anti-fibrotic, anti-inflammatory agent that is currently 
used to treat idiopathic pulmonary fibrosis and has been investigated as a potential 
treatment for DKD (	  Scleroderma	  Research	  Foundation, n.d.). Animal models have 
shown pirfenidone may inhibit TNF-α in addition to TGF-β thereby acting in a 
multifaceted way to combat disease progression (Mathew et al., 2011). Prifenidone has 
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been studied in diabetic patients; however those involved were a mix of patients with 
type I and type II diabetes. Sharma et al. showed that subjects taking Pirfenidone at 1200 
mg a day had better renal outcomes compared to subjects taking placebo as well as 
subjects taking Pirfenidone at 2400 mg a day. The primary endpoint of this study was 
change in eGFR after one year of treatment with either placebo or one of two doses of 
Pirfenidone. At the end of the twelve-month treatment period the subjects taking 1200 mg 
of Pirfenidone experienced a mean increase in eGFR of 3.3 ml/min per 1.73m2 whereas 
subjects in both the placebo group and 2400 mg of Pirfenidone daily group did not 
experience any significant changes in eGFR. These results suggest Pirfenidone as a 
viable therapeutic agent for DKD. However, renal biopsies were not performed in this 
study, therefore the improvement in eGFR cannot be definitively attributed to the anti-
fibrotic properties of Pirfenidone (Sharma et al., 2011). The etiology of type I and type II 
diabetes is different. Therefore to determine the therapeutic benefit of pirfenidone for 
DKD due to type II diabetes a study would need to be conducted utilizing only a type II 
diabetic population.  
 The increased blood glucose concentration associated with diabetes mellitus leads 
to the formation of advanced glycation end products that directly and indirectly 
contribute to the progression of diabetic kidney disease. On their own AGEs contribute to 
glomerular hypertrophy and sclerosis thereby damaging the filtering unit of the kidney 
and promoting proteinuria. AGEs also increase the expression of pro-inflammatory 
cytokines and growth factors thus enhancing their deleterious effects on the kidney 
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(Alicic & Tuttle, 2014). For their multifactorial contribution to the progression of DKD, 
AGEs serve as an excellent target for therapeutic intervention.  
 Pyridoxamine is a vitamin B derivative that is hypothesized to prevent formation 
of AGEs thus delaying the progression of DKD as well as preserving renal function. Data 
show that pyridoxamine is only effective in patients with greater baseline renal function 
thus the only patients that would benefit from potential treatment are those who have 
their DKD discovered early in the disease process (Lewis et al., 2012). The 
manufacturing of a novel therapeutic drug is an expensive and timely process. With that 
in mind the focus for DKD treatment should remain on therapeutic options that serve a 
broader group of patients. Diabetic kidney disease is on the rise and unfortunately will 
not always be caught early therefore it is important that potential agents for this disease 
be able to work across a broad spectrum of renal function in order to benefit the greatest 
number of patients.  
 In addition to being harmful to renal cells on their own, inflammatory cytokines 
take on another role in DKD progression in their ability to activate the transcription factor 
NF-κB. NF-κB, once activated, initiates the transcription of more inflammatory cytokines 
thereby enhancing inflammation and tissue destruction. Two natural derivatives of plants, 
L6H21 and B06 have been shown to inhibit enhanced inflammatory cytokine production 
in in vitro studies by inhibiting NF-kB (Ahad et al., 2014; Fang et al., 2015). When B06 
was introduced into an animal study, investigators observed no histopathological changes 
in rats treated with B06 (Pan et al., 2013). L6H21 was studied in animal models of type I 
diabetes and yielded positive results. Diabetic induced rats that were treated with L6H21 
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expressed decreased concentrations of inflammatory cytokines and did not display the 
histopathological changes associated with DKD (Fang et al., 2015). Both of these 
compounds have not been extensively studied for the treatment of DKD nor have they 
been introduced to humans for this purpose but they both show great promise. The next 
step would be to continue animal studies in subjects induced with type II diabetes in 
attempts to reproduce these results as well as begin to ascertain a safety and tolerability 
profile.  
 The chronic inflammation associated with type II diabetes is not isolated to one 
area of the body such as the kidneys but rather is the result of the activation of the 
immune system in its entirety. Mycophenolate mofetil is an immunosuppressant that is 
currently used to treat autoimmune diseases and has been studied in animal models for 
the treatment of DKD. Data from Utimura et al. 2003 revealed MMF has antiproteinuric 
properties however it is with great caution that this drug should be used for treating 
patients with DKD. As an immunosuppressant, this treatment option would not only 
suppress immune activation in the kidney but in the entire body leaving patients 
susceptible to illness. Mycophenolate mofetil was also observed to inhibit glomerular 
macrophage infiltration which investigators determined to be an early step in disease 
pathogenesis. This would imply that the therapeutic effects of MMF are most beneficial 
to those who are in the early stages of disease progression. It is unknown whether MMF 
can reverse the disease and therefore MMF may not be effective in patients with 
decreased renal function. Further investigation would need to be done in animal models 
to confirm the action of MMF in regards to treating DKD and determine if the risk of 
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utilizing an immunosuppressant for the treatment of DKD is outweighed by the potential 
benefit (Utimura et al. 2003).   
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CONCLUSIONS 
 
 Diabetic nephropathy is a complex and devastating disease that is difficult to 
definitively diagnose in patients. This is the result of varying definitions as to what 
exactly is diabetic nephropathy. It is widely accepted to use three defining characteristics 
for diagnosis: chronic albuminuria, defined as greater than or equal to 300 mg of albumin 
in the urine per day, decreased GFR and increased blood pressure (Medscape, 2014). 
These markers are not enough however as they have each their own limitations that may 
result in delayed diagnosis and treatment. In order to be able to treat these patients there 
needs to be a defined standard that physicians can utilize to diagnose DKD. This would 
also aid in early intervention thereby improving renal outcomes for patients and delaying 
as well as possibly preventing progression to end stage renal disease and the need for 
renal replacement therapy. 
There is a great need for additional treatment to the current standard of care in 
order to prevent the progression of disease and avoid total kidney failure. Not only would 
this improve quality of life but would also save millions of dollars in health care 
spending. The studies presented all have their own limitations including: small patient 
population or no human population at all, lack of placebo and lack of investigator 
blinding to study treatment. These studies lack power and data. In order for these drugs to 
be viewed as serious candidates for the treatment of DKD there need to be larger trials 
that can produce not only positive, reproducible results but also safety and tolerability 
data in human subjects.  
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It is also important to note the drugs being studied are interfering with the 
immune system, a system that is ubiquitous throughout the body and suppressing it and 
its components can have serious side effects. These drugs may leave patients susceptible 
to serious illness that is why long-term data need to be established to determine if the 
benefits of these drugs outweigh the risk. 
Urinary concentrations and renal cortical mRNA concentrations of TNF-α are 
some of the earliest clinical signs of a patient that has DKD and are extremely important 
in regards to patients progressing to end stage renal disease (Navarro & Mora-Fernández, 
2006). Rise in TNF-α concentrations often precede microalbuminuria, the first clinical 
sign of DKD. Patients with type II diabetes and microalbuminuria are at a 42% greater 
risk of developing overt nephropathy and DKD compared to those who are 
normoalbuminuric (Bruno et al., 2003). The importance of TNF-α to disease progression 
is evident, thereby making it the best inflammatory biomarker to target in order to combat 
DKD. Routine testing of urinary TNF- α concentration in addition to the current battery 
of tests that patients with diabetes must undergo would increase the chances of early 
disease detection allowing for early intervention.  
As early detection is critical to treatment and prevention of disease progression 
the investigational products that fall under the category of TNF-α inhibitors are those that 
should be further pursued in the treatment of DKD. In comparison to other potential 
therapeutic interventions, PTX has been more extensively studied in patients with DKD 
due to type II diabetes. Although each study has its respective limitations, PTX has 
consistently shown to delay the progression of DKD as well as provide greater renal 
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protection compared to the current standard of care for DKD (Ghorbani et al., 2012; 
Navarro-González et al., 2015; Navarro & Mora, 2005). PTX can also be used in addition 
to ACEI and ARB therapy which is beneficial to diabetic nephropathy patients as this 
therapeutic regimen would not only delay disease progression from an inflammatory 
standpoint but also help to control the hemodynamic perturbations associated with this 
disease. At this point in time efforts to combat DKD should be focused on research 
regarding treatment with PTX to determine long-term effects of PTX in subjects with 
DKD.  
Among the other TNF-α inhibitors chrysin stands out the most for its 
hypothesized ability to prevent diabetic kidney disease. Chrysin was administered 
immediately upon induction of diabetes in the presented study (Ahad et al., 2014). Those 
rats that received chrysin treatment did not show any clinical manifestations of DKD nor 
were there histopathological changes observed in these rats. This study implies that 
chrysin is a compound that could be given upon diagnosis of type II diabetes and would 
prevent nephropathy from taking place. This is drastically different from PTX that is 
administered to subjects with a previously established diagnosis of DKD. At this point in 
time animal studies with chrysin need to be repeated to provide a supportive foundation 
for investment into this drug as a potential therapeutic for diabetic nephropathy. With 
continued positive results from pre-clinical studies arises the possibility of moving 
chrysin into clinical trials with the end goal of becoming FDA approved for the treatment 
of DKD.  
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The target for therapeutic intervention for diabetic kidney disease has been 
identified. It is now the time for extensive time and effort to be invested into TNF-α 
inhibitors to produce a novel therapeutic agent to combat this globally devastating 
disease. The ideas and foundation are there, the extensive patient population is present; it 
is now up to industry and sponsoring health agencies to invest research and financial 
support in these drugs which have the potential to greatly impact modern medicine.  
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VITA 
 
AMANDA R. CORREIA 
 
153 Richard Drive 
 Tiverton Rhode Island 02878 
Correia8@bu.edu 
1990 
  
Technical Skills                                                                                                                                        
• Proficient in Microsoft Word, Excel and PowerPoint 
• Proficient in Spanish 
  
Work Experience                                                                                     
• Clinical Research Assistant  
o July 2012 – August 2013; June 2014 to present 
o Rhode Island Hospital - Providence, Rhode Island 
o Responsible for assisting the clinical research coordinator with seeing 
patients, running labs and data entry.   
• EMT Basic 
o November 2011 – January 2013 
o New England Ambulance – Johnston RI 
o Responsible for transporting patients to and from hospitals and providing 
necessary medical interventions based on patient assessment and knowledge 
of the situation. 
• General/Organic Chemistry Lab Teaching Assistant 
o September 2009 to May 2011 
o Providence College – Providence RI 
o Responsible for setting up the experiment, running and cleaning various 
pieces of equipment and assisting the students as needed. 
• Dietary Aide/Resident Program Assistant  
o April 2007 to present 
o Sakonnet Bay Manor – Tiverton, Rhode Island 
o Responsible for serving, clearing and cleaning the dining room. After a year 
gained a position of greater responsibility and leadership within the dietary 
staff as an opener and closer. In 2011 I switched to the activities department 
where my new job entailed working directly with the residents to improve 
their quality of life.  
 
Education and Training                                                                            
• Boston University School of Medicine, 2015 
o Boston, Massachusetts, United States 
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o Degree: Masters of Science 
o Major: Medical Science 
• Providence College, 2012 
o Providence, Rhode Island, United States 
o Degree: Bachelor of Science 
o Major: Biology 
o Alpha Epsilon Delta pre-medical national honor society member 
• American Safety Programs, 2010 
o Providence, Rhode Island, United States 
o Emergency Medical Technician - Basic 
o Licensed EMT-Basic in the state of Rhode Island. 
o Nationally certified EMT-Basic. 
o CPR Certified 
 
Clinical Research Experience 
• Role: Research Assitant/Coordinator 
o SAVOR: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients 
with Diabetes Mellitus. A Multicenter, Randomized Double Blind Placebo 
Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the 
Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke 
in Patients with Type 2 Diabetes 
! TIMI Study Group 
! 07/2012 – 08/2013 
o A Randomized Double-Masked, Place Controlled, Multicenter Phase 2 Study 
to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients with 
Type 2 Diabetes. 
! Eli Lilly 
! 07/2012 – 08/2013, 06/2014 – 08/2014 
o A Phase III Multicenter, Two-phase, Multi-dose, Prospective, Randomized, 
Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy 
of ZS (Microporous, Fractionated, Protonated Zirconium Silicate) and Oral 
Sorbent, in Subjects with Mild to Moderate Hyperaklemia 
! ZS Pharma 
! 11/2012 – 08/2013 
o Randomized Double Blind Parallel-Group MultiCenter Study to Evaluate the 
Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa 
(Epogen/Procrit) in the treatment of Anemia Associated with Chronic Kidney 
Disease 
! Sandoz 
! 06/2013 – 08/2013, 06/2014 – 01/2015 
o An exploratory Phase 2, randomized, double-blind, placebo-controlled, 
parallel design study to evaluate the safety, tolerability, and 
pharmacodynamics of AZD1722 in CDK patients with type 2 diabetes 
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mellitus and albuminuria 
! Ardelyx Inc. 
! 04/2013 – 08/2013, 06/2014 – 03/2015 
o Sleep Apnea, Cardiovascular Risk and Chronic Kidney Disease 
! Private donor 
! 06-2014 – present 
o SONAR: Study of Diabetic Nephropathy with Atrasentan A Randomized, 
Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study 
of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 
Diabetes and Nephropathy 
! AbbVie 
! 06-2014 – present 
o An open-label extension to study ZS-004, a Phase 3 Multicenter, Multi-phase, 
Multi Dose, Prospective, Randomized, Double-blind, Placebo-controlled 
Maintenance Study to Investigate the Safety and Efficacy of ZS (Sodium 
Zirconium Cyclosilicate), an Oral Sorbent, in Subjects with Hyperkalemia 
! ZS Pharma 
! 06/2014 – present  
o A Phase 3 Multicenter, Multi-dose, Open-label Maintenance Study to 
Investigate the Long-term Safety and Efficacy of ZS (Sodium Zirconium 
Cyclosilicate), an Oral Sorbent, in Subjects with Hyperkalemia, Including a 
Randomized, Double-blind, Placebo-controlled, Withdrawal Study 
! ZS Pharma 
! 10/2014 – present 
o A Phase 3 Randomized, Double Blind, Placebo Controlled, Multi-Center 
Study to Evaluate the Safety and Efficacy of Pyridorin (pyridoxamine 
dihydrochloride) in Subjects with Nephropathy Due to Type 2 Diabetes 
! Nephrogenix 
! 11/2014 – present 
 
Volunteer Experience                                                                           
• Mobility Volunteer 
o February 2014 – present 
o Newport Hospital – Newport, RI 
o Responsible for taking patients for walks around the unit in order to aid 
recovery and potentially decrease recovery time.  
 
